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Abstract
Nisin is an antimicrobial peptide commonly used as a food preservative since 1969. This 
peptide has potent antimicrobial activity against several Gram-positive bacterial strains, 
including clinically important and resistant pathogens. The combination of nisin with 
conventional antibiotics has been shown to improve the antimicrobial activity of these 
antibiotic agents. Apart from the antimicrobial properties of nisin, this AMP also displays 
promising anticancer potential towards several types of malignancies. The nisin Z vari-
ant is able to induce selective cytotoxicity in melanoma cells compared to non-malignant 
cells. It was shown that nisin Z disrupts the cell membrane integrity of melanoma cells 
and that cytotoxicity is likely due to the activation of an apoptotic pathway. In addition, 
when used in combination with the conventional chemotherapeutic agents, nisin Z has 
the potential to enhance the cytotoxicity of these chemotherapeutic agents against cul-
tured melanoma cells. Nisin Z has great potential for clinical application considering its 
low cytotoxicity to non-malignant cells and its effectiveness against Gram-positive bacte-
rial strains and certain cancers.
Keywords: melanoma, antimicrobial peptide nisin Z, combination therapy, selective 
cancer cytotoxicity, chemotherapeutic agents, antibiotic resistance
1. Introduction
Antimicrobial peptides (AMPs) are produced by all known living species and exhibit direct 
microbial killing activity while also playing an important role in the innate immune system [1]. 
This diverse group of peptides is found in all living species and may be promising alternatives 
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or serves as additives to current antibiotics [2–4]. Many of the more than 2000 known AMPs 
have been demonstrated to exhibit broad-spectrum antibacterial activity [5], and bacteria are less 
likely to develop resistance to these peptides compared to conventional antibiotics [6, 7].
The lantibiotic nisin, produced by Lactococcus lactis, has promising potential for clinical appli-
cation with its Generally Regarded as Safe (GRAS) status. This AMP was approved by the World 
Health Organisation (WHO) in 1969 and the US Federal Food and Drug Administration (FDA) 
in 1988 for the use as a food preservative [8]. Despite being extensively utilised for food pres-
ervation for nearly 50 years, there is very little indication of resistant mutants arising in food 
products treated with this AMP [8, 9].
Nisin is primarily used for its antibacterial activity. However, AMPs, and especially bacterio-
cins, display selectivity towards cancer cells [10]. Due to the toxicity associated with many con-
ventional chemotherapeutic agents, as well as the development of chemotherapy resistance 
[11–13], there is a need for the development of novel anti-cancer therapies. Furthermore, to 
overcome chemotherapy resistance, the efficacy of chemotherapeutic agents can be enhanced 
by the co-administration of multi-functional agents to achieve synergistic interactions [14, 
15]. The ability of nisin to increase the activity of the chemotherapeutic drug doxorubicin was 
investigated in vivo by Preet and co-workers. Nisin, when used in combination with doxoru-
bicin, enhanced the anti-cancer activities of doxorubicin. Apoptosis could be detected upon 
treatment of mice with induced skin carcinogenesis. However, the exact mechanism by which 
nisin exerts its anti-cancer activities was not known [16].
2. Antimicrobial properties of the antimicrobial peptide nisin
A report published in 2016 projects that resistance to antibiotics could potentially lead to 
10 million deaths per year by 2050 [17]. Moreover, the estimated economic impact of micro-
bial resistance will be massive, costing nearly 100 trillion US dollars while leading to sharp 
decreases in the gross domestic product. Microbial resistance against conventional antibiotic 
agents is a serious hazard to the effective treatment of numerous diseases. This upsurge in 
antibiotic resistance has stimulated research into the development of alternative antimicrobial 
agents. Antimicrobial peptides are considered promising alternatives to current antibiotics 
and have the potential to replace certain antibiotics or to be used synergistically in combina-
tion with existing antimicrobial agents [2, 18].
2.1. Anti-bacterial effects of Nisin
Nisin was discovered in the same year as penicillin, but was quickly overshadowed by this anti-
biotic due to penicillin’s ease of mass production and low manufacturing costs [19]. Nisin is a 
3.5 kDa polycyclic peptide consisting of 34 amino acids and is produced by the non-pathogenic 
bacteria Lactococcus lactis [20]. Two naturally occurring variants of this peptide are nisin A and 
nisin Z. These two variants are structurally identical with the exception a single amino acid at 
position 27, where histidine occurs in nisin A while asparagine is found in nisin Z [20]. Both 
variants display similar antimicrobial activity but nisin Z is more soluble at neutral pH [21, 22].
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In Gram-positive bacteria, nisin exhibits a dual mode of action by binding to lipid II on the 
bacterial membrane resulting in the inhibition of cell wall synthesis and the formation of 
pores in the bacterial cell membrane [23]. The antimicrobial effects of nisin Z against Gram-
negative bacteria are largely inadequate. However, the activity towards Gram-negative bac-
teria can be improved by using ethylenediaminetetraacetic acid (EDTA) and the non-ionic 
surfactant Tween®80 [24, 25] (Figure 1).
The glycopeptide antibiotic, vancomycin, also binds to lipid II to inhibit cell wall synthe-
sis, albeit at a different amino acid moiety. Vancomycin is one of the last line treatments 
against several Gram-positive antibiotic-resistant bacteria including methicillin-resistant 
Staphylococcus aureus (MRSA) [26, 27]. Disturbingly, clinical variants of MRSA have been 
isolated of which the lipid II pentapeptide have mutated to acquire resistant to vancomy-
cin. These strains contain the vanA-type gene cluster where the terminal D-Ala has been 
changed to D-Lactate in the lipid II pentapeptide [28]. Due to its different binding motif, 
nisin remains active against the vanA-type resistant strains [29]. This shows the potential 
of nisin to bolster the antimicrobial defences against antibiotic-resistant bacterial strains. 
Nisin has a promising potential for clinical application with its GRAS status and approval 
by both the FDA and WHO, considering its low cytotoxicity and the fact that it is con-
sidered safe for human consumption. Currently, it is employed as a food preservative 
in nearly 50 countries to guard food against spoilage resulting from pathogens such as 
Staphylococcus aureus, Listeria monocytogenes, and Clostridium botulinum [30]. In addition, 
nisin has also been demonstrated to possess antibacterial activity against several clinically 
Figure 1. Minimum inhibitory concentrations (MIC) of nisin Z for Gram-positive and Gram-negative bacterial strains. 
The effect of EDTA (200 μM) on the MIC of E. coli is also demonstrated.
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relevant  pathogens including vancomycin-resistant Enterococci, Streptococcus pneumonia, 
and methicillin- resistant Staphylococcus aureus [31, 32].
Mastitis-causing Staphylococcus strains have a tendency to develop resistance to antibiotics [33, 
34]. Nisin has been successfully applied as a sanitizer against mastitis causing Staphylococcus 
and Streptococcus species in lactating cows even when these species are antibiotic resistant [35, 
36]. Three nisin-based products were developed for the treatment of bovine mastitis, namely 
Ambicin N® (Applied Microbiology, Inc., New York) and Mast Out® as well as Wipe Out® 
Dairy wipes (ImmuCel Corporation, Maine, USA) [30]. In vivo nisin has also been shown to 
be an effective and safe alternative to antibiotics in the treatment of staphylococcal mastitis 
during lactation in pregnant women [37].
Antibacterial agents possessing various modes of action are particularly of interest in the 
fight against antimicrobial resistance as it is considered to be more challenging for bacteria 
to develop resistance against multiple mechanisms concurrently. This has proven true in the 
case of nisin, as there is very little evidence of transmissible and stable resistance occurring 
after nearly 50 years of treating food products with this AMP [37–39].
2.2. AMPs as antibiotic adjuvant therapy
The discovery and subsequent development of a wide range of antibiotics have revolu-
tionised modern health care. Over the last century, the introduction of antibiotics drasti-
cally reduced morbidity and mortality. Today, antibiotics are readily available to the global 
population, and effective antibiotic agents have been developed against the majority of 
illness-causing bacteria. Ironically, the success of antibiotics has resulted in these drugs 
being misused, leading to the accelerated development of antimicrobial resistance amongst 
many bacterial species. Antibiotic resistance is making the effective treatment of numer-
ous infections no longer achievable and there is a pressing need for alternative therapeutic 
approaches.
Antibiotic adjuvant therapy (to achieve synergistic interactions, although additive interactions 
are also favoured) can be considered as a promising strategy to combat antibiotic resistance. 
Combination of antibiotics and AMPs that possess different modes of action are valuable in 
the fight against antimicrobial resistance as it is unlikely for bacteria to develop resistance 
against multiple mechanisms simultaneously. Several studies have demonstrated synergism 
between nisin and conventional antibiotics. Nisin displayed synergism with the antibiotics, 
colistin and clarithromycin, against the common Gram-negative bacteria, Pseudomonas aeru-
ginosa [40]. Synergistic effects were also observed with streptomycin, penicillin, rifampicin 
and lincomycin against P. fluorescens as well as the antibiotic-resistant variants of this strain 
[41]. Daptomycin, teicoplanin and ciprofloxacin displayed synergism against MRSA biofilms 
[4]. In a study by Dosler and Gerceker, nisin-antibiotic combinations were shown to have 
synergistic interactions against clinical isolates of methicillin-susceptible S. aureus (MSSA), 
MRSA and Enterococcus faecalis. A major finding from their study was that a high incidence 
of synergistic interactions occurred with a nisin-ampicillin combination against MSSA and 
nisin-daptomycin combination against E. faecalis strains [42]. When nisin is combined with 
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penicillin, chloramphenicol or ciprofloxacin, biofilm formation of E. faecalis was significantly 
reduced [43].
In a previous study, we also evaluated the interaction of the nisin Z variant with conven-
tional antibiotics [24]. Antibiotic-nisin Z combinations (1:1) were evaluated on Staphylococcus 
epidermidis (ATCC 12228) and Staphylococcus aureus (ATCC 12600) seeing as nisin is princi-
pally effective against Gram-positive bacterial species. Several conventional antibiotics with 
different mechanisms of action against Gram-positive bacteria were selected and included 
methicillin; vancomycin; ampicillin; tetracycline; gentamicin and novobiocin. The minimum 
inhibitory concentration (MIC) was used as a reflection of the bacterial cytotoxicity following 
exposure to the antibiotic-nisin Z combinations. The MIC was determined using a modi-
fied broth microdilution method [44], where the p-iodonitrophenyltetrazolium violet (INT) 
was replaced with the yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT). The interactions between the antibiotics and nisin were deter-
mined using the fractional inhibitory concentrations (FIC) [45] and values were interpreted 
as ƩFIC ≤0.5 synergistic, ƩFIC >0.5–1.0 additive, ƩFIC >1.0 and <4.0 indifferent and ƩFIC ≥4.0 
antagonistic.
Bacterial treatment with nisin Z-antibiotic combinations resulted in the identification of three 
additive and two synergistic combinations. Nisin Z displayed an additive effect (ƩFIC >0.5 to 1.0) 
when combined with ampicillin and gentamicin in S. aureus (Table 1).
Bacterial strain MIC of nisin Z (μg/ml) MIC of antibiotic (μg/ml) Nisin Z:antibiotic (1:1)
ƩFIC
S. epidermidis Nisin Z (9.17) Methicillin (1.88) 2.68
Vancomycin (2.50) 2.55
Ampicillin (16.67) 0.71
Tetracycline (80.00) 3.65
Gentamicin (1.04) 2.23
Novobiocin (1.46) 0.50
S. aureus Nisin Z (10.00) Methicillin (1.88) 1.06
Vancomycin (2.50) 2.50
Ampicillin (1.04) 0.66
Tetracycline (0.47) 1.40
Gentamicin (6.67) 0.94
Novobiocin (2.29) 0.17
Highlighted values represent ƩFIC values which indicate positive interactions between nisin Z and antibiotics where; 
≤0.5 synergistic, >0.5–1.0 additive, 1.1–3.9 indifferent and ≥4.0 antagonistic.
Table 1. MIC values and ƩFIC values for antibiotic-nisin Z combinations.
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Furthermore, S. epidermidis treated with ampicillin-nisin Z combination also showed an 
additive interaction. Novobiocin-nisin Z combinations showed synergistic interactions 
when used against S. epidermidis and S. aureus. Novobiocin, as part of the aminocoumarins 
antibiotic group, is able to indirectly block DNA replication by effectively inhibiting bacte-
rial DNA gyrase. Novobiocin-nisin Z combination was particularly effective in the treatment 
of S. aureus as a dramatic reduction in the ƩFIC was witnessed. This may be due to the dif-
ferent, but complementary, mechanisms of actions of nisin Z and novobiocin. As the lipid 
II-nisin Z complex forms pores in the bacterial membrane, hydrophobic novobiocin can pass 
through the cell membrane to interact with the DNA gyrase of S. aureus. This is only specula-
tion and the exact synergistic mechanism of should be examined further. This in vitro study 
shows the potential of nisin Z for the use as an adjuvant with conventional antibiotics. AMP-
antibiotic combination therapy may aid in reinforcing the defences against resistant organ-
isms by making it more challenging for a bacterial strain to adapt to multiple antimicrobial 
mechanisms. Furthermore, novobiocin is used for the treatment of mastitis in lactating cows 
[46]; and as previously mentioned, some nisin-based products have been developed for the 
treatment of mastitis. The synergistic interactions between nisin and novobiocin make this 
combination especially of interest for developing novel formulations for the treatment of 
mastitis.
3. Cytotoxic effects of nisin on non-malignant mammalian cells
It is clear that nisin is an effective antimicrobial agent which can inhibit the growth of/kill sev-
eral Gram-positive bacterial species, including food-borne pathogens such as Staphylococcus 
aureus, Listeria monocytogenes and Clostridium botulinum as well as exhibiting activity 
against many clinical important pathogens such as vancomycin-resistant Enterococci (VRE), 
Streptococcus pneumonia and MRSA [32, 47, 48]. Despite having exceptional antimicrobial 
activity, many AMPs also exhibit high toxicity to mammalian cells. An example of a cytotoxic 
AMP is melittin, the main active component of apitoxin (bee venom). Melittin has an excellent 
antibacterial activity and the antimicrobial mechanism of this AMP is most likely the permea-
bilisation of cell membranes by pore formation resulting in cell lysis and death [49]. Although 
melittin has effective broad-spectrum antimicrobial activity, this AMP is extremely toxic to 
mammalian cells even at very low concentrations.
As mentioned before, nisin has a Generally Regarded as Safe (GRAS) status and is considered 
safe for human consumption. The Accepted Daily Intake (ADI) of nisin was determined 
by the FDA as 2.94 mg/per day (0.049 mg/kg body weight/day) in 1988, prior to receiving 
GRAS status [50]. In a study by Joo and co-workers, mice were exposed to a concentra-
tion of nisin more than ×1000 (150 mg/kg body weight/day) the recommended ADI over a 
period of 3 weeks with no signs of cytotoxicity [51]. In another study, mice were treated 
with doses of 800 mg/kg body weight/day (more than 10 000 times higher than the recom-
mended ADI) ultra-pure nisin Z for 3 weeks without any evidence of toxicity [52]. In both 
these studies, long-term (>3 weeks) treatment with high concentrations of nisin did not 
result in any observable toxicity.
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We also investigated cytotoxicity of nisin Z towards mammalian cells using the MTT assay to 
measure metabolic activity and the lactate dehydrogenase (LDH) assay to indicate membrane 
integrity. The non-malignant human immortalised keratinocyte (HaCaT) cells were employed 
for cytotoxicity testing and cultured under normal conditions [24]. Briefly, HaCat cells were 
seeded in a 96-well plate and incubated until ~90% confluent. Synthetic melittin was used 
(≥97% HPLC from Sigma-Aldrich) as a positive AMP control for cytotoxicity. After 24 h of 
exposure to nisin Z or melittin (2.5–40 μg/ml), the MTT assay was performed as described pre-
viously [24]. The ability of NAD(P)H-dependent cellular oxidoreductase enzymes to reduce 
MTT to formazan is considered a reflection of the number of viable cells present. Cell viability 
is expressed as a percentage relative to the untreated control, which was set as being 100% 
viable. For an assay positive control, cells were exposed to 0.01% Triton-X 100 (Sigma-Aldrich, 
St Louis, MO, USA).
To investigate the effect of the two AMPs on cell membrane integrity, the CytoTox-ONE™ 
Homogeneous Membrane Integrity Assay (Promega, Madison, WO, USA) was employed. 
This assay determines the release of lactate dehydrogenase (LDH) into the culture media 
from cells with impaired cell membranes. HaCat cells were exposed to melittin and nisin Z 
as described earlier. A lysis solution (Promega) was used as a maximum LDH release posi-
tive control. The LDH release assay was performed as described previously [24]. Results are 
conveyed relative to the untreated control (set to 0% LDH release) and the maximum release 
sample (set to 100% LDH release).
Cytotoxicity data (Figure 2) shows that nisin Z did not negatively affect the cell viability of 
HaCat cells.
The MTT assay indicates that the ability of NAD(P)H-dependent cellular oxidoreductase 
enzymes to reduce MTT to formazan was not affected by the exposure to the tested nisin 
Figure 2. Cytotoxicity assay of HaCat cells exposed to the AMPs melittin and nisin Z. (A) MTT assay and (B) LDH release 
assay. Vehicle control groups are represented by 0 mg/ml. Values represent mean stdev n = 3. ***p < 0.001 compared to 
the vehicle control group.
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Z concentrations. Indicating that nisin Z did not negatively affect the cell viability of HaCat 
cells. The LDH assay also showed that there was no significant increase in the release of LDH, 
indicating that nisin Z did not cause any measurable membrane damage. On the other hand, 
both the MTT and LDH assays showed that relatively low concentrations of melittin led to a 
considerable increase in cytotoxicity in HaCat cells.
These in vitro results eco many of the recent in vivo findings, showing that nisin exposure to 
non-malignant cells has very little to no cytotoxic effects. Even at concentrations of nisin Z that 
exceeds the MICs for S. aureus and S. epidermidis (Figure 1) no toxicity was observed. Keeping 
in mind that nisin is an effective antimicrobial agent against several Gram-positive bacte-
rial species, including clinical important and resistant pathogens, this AMP shows promising 
potential for clinical application.
4. Cytotoxic effect of nisin on malignant cells
Over the last few decades, great strides have been made in cancer treatment and therapies, 
leading to the steady decline of cancer death rates [53]. Despite these developments, many 
current cancer therapies are still associated with high cytotoxicity and lack specificity. There is 
consequently still a need for the development of novel anti-cancer therapies. AMPs, especially 
bacteriocins, display selectivity towards cancer cells [10]. These AMPs are, therefore, potential 
alternative candidates to current chemotherapeutic agents. AMPs can also be applied as adju-
vants to chemotherapeutic agents to lower the therapeutic doses needed with the intention of 
quelling the toxicity of these treatments.
Studies have previously investigated the anti-tumour potential of nisin in vitro and in vivo 
for head and neck squamous cell carcinoma (HNSCC) [52]. The study by Joo and co-workers 
indicated that nisin has the ability to selectively induce apoptosis, cell cycle arrest and reduce 
cell proliferation in HNSCC cells, compared to primary keratinocytes in vitro [51]. In vivo, 
nisin treatment reduced the overall tumour burden compared to non-nisin treated groups, 
in a floor-of-mouth oral cancer xenograft mouse model. Also, to examine the mechanism by 
which nisin facilitates its anti-proliferative and pro-apoptotic effects on HNSCC cells, the 
effect of nisin-treatment on the expression of 39,000 genes was examined by using Affymetrix 
gene arrays. The expression of multiple genes was altered, including those in the apoptotic 
and cell cycle pathways, membrane physiology, energy and nutrient pathways, ion transport 
and signal transduction and protein binding pathways. The CHAC1 gene, a cation transport 
regulator and apoptosis mediator were dramatically up-regulated. This study was the first 
to show that the antibacterial food preservative nisin could effectively reduce and prevent 
tumorigenesis both in vitro and in vivo.
4.1. Cytotoxic effects of nisin Z on melanoma cells
We also evaluated the potential of nisin Z to induce selective cytotoxicity towards human 
melanoma cells in vitro. Melanoma is the leading cause of skin cancer-related deaths [54, 55]. 
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Contrary to most types of cancer, the frequency of melanoma has been increasing over the last 
three decades [54]. In addition to a high mortality rate, Melanoma cells also have a sinister ten-
dency to rapidly develop resistance to mainstream chemotherapeutic agents [12, 13]. In vitro 
cytotoxicity of the nisin Z was determined by employing the MTT assay, LDH assay and flow 
cytometric apoptosis and necrosis analyses. The non-malignant human keratinocyte (HaCat) 
cell line was used as a control. The MTT and LDH assays were performed, as described pre-
viously [56]. The flow cytometric FITV Annexin V apoptosis assay (BD PharmingenTM, BD 
Biosciences, San Jose, CA, USA) was employed for the detection of apoptotic cytotoxicity. 
FITC Annexin emits green fluorescence and its presentation indicates early apoptotic events, 
while propidium iodide (PI) emanates red fluorescence and is associated with late apoptotic 
or necrotic cells.
The quantitative colourimetric MTT assay was used to investigate the cytotoxic effect of nisin Z on 
cultured melanoma cells as well as non-malignant keratinocytes. There is a clear concentration-
dependent decline in cell viability observed in melanoma cells exposed to nisin Z (Figure 3A).
Figure 3. Cytotoxic effects of nisin Z on melanoma (A375) cells. (A) Cell viability was determined using the MTT assay. 
(B) LDH release from cells following treatment with nisin Z. Keratinocytes (HaCat) were used as a non-malignant 
control. * p< 0.05 and *** p< 0.001 compared to the control groups.
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A significant increase in cytotoxicity is observed in melanoma cells after exposure to rela-
tively low concentrations of nisin Z. The IC
50
 value of melanoma cells exposed to nisin Z 
is approximately 180 μM. Conversely, the non-malignant keratinocytes exposed to nisin Z 
presented with considerably higher cell viability, with an IC
50
 value more than double that 
of its malignant counterpart. To examine whether the observed cytotoxicity of melanoma 
cells exposed to nisin Z is the result of membrane damage, the LDH assay was performed. 
This assay measures the release of lactate dehydrogenase, the cytosolic enzyme, as a result 
of cellular plasma membrane damage. Results suggest that the exposure of melanoma cells 
to nisin Z concentrations of 150 μM and higher (Figure 3B) lead to in a significant increase 
in LDH release. No significant LDH release was detected in the non-malignant keratinocytes 
after nisin Z exposure, indicating very little membrane damage. Both, the basic cytotoxicity 
assays (MTT and LDH assay) suggest that nisin Z is selectively more toxic towards cultured 
melanoma cells compared to non-malignant cells.
Flow cytometry was used to investigate whether the cytotoxicity observed in melanoma cells 
was of apoptotic or necrotic origin. For the non-malignant keratinocyte cells, the flow cyto-
metric analysis indicated that >98% of the cells exposed to 50 μM nisin Z could be considered 
viable and is comparable to the untreated control (Figure 4).
A small increase in cytotoxicity is observed at higher concentration. Melanoma cells exposed 
to 50 μM nisin Z showed a much larger early apoptosis (>17%) population than their non-
malignant counterparts. A significant increase in cytotoxicity is observed in melanoma cells 
exposed to higher concentrations of nisin Z, resulting in approximately half of the cancer cells 
undergoing apoptosis/necrosis after being exposed to nisin Z concentrations of 100 μM or 
higher. These results confirm the basic viability data that nisin Z is more selectively cytotoxic 
to melanoma cells and give an indication that the cell death observed in these cells is probably 
due to the activation of an apoptotic pathway.
Figure 4. Pie graphs representing the cell population sizes of viable, apoptotic and necrotic non-malignant keratinocyte 
(HaCat) and melanoma (A375) cells after exposure to 50–200 μM of nisin Z for 24 h.
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4.2. The potential of nisin Z to increase the cytotoxicity and selectivity of 
conventional chemotherapeutic agents
Due to the toxicity associated with some conventional chemotherapeutic agents, as well as the 
constant threat of malignancies evolving chemotherapy resistance [11–13], there is a neces-
sity for the development of novel anti-cancer therapies. To combat chemotherapy resistance, 
the efficacy of chemotherapeutic agents can be enhanced by the co-administration of multi-
functional agents to achieve synergistic interactions [14, 15].
As stated earlier, there is an abundance of studies which investigated the use of nisin as an 
adjuvant to conventional antibiotics [4, 40–42, 57]. It has been shown that nisin displays anti-
cancer properties; however, inadequate focus has been given to applying nisin as an adjuvant 
for chemotherapeutic agents. The ability of nisin to increase the activity of the chemothera-
peutic drug, doxorubicin, was investigated in vivo by Preet and co-workers [16]. Doxorubicin 
(Adriamycin) is traditionally employed to treat breast cancer, bladder cancer, lymphoma, 
and acute lymphocytic leukaemia, to name a few. When combining nisin with doxorubicin, 
enhanced anti-cancer activities were observed and apoptosis could be detected upon treat-
ment of mice with induced skin carcinogenesis as well as a slight increase in oxidative stress. 
However, the exact mechanism by which nisin exerts its anti-cancer activities was not deter-
mined [16]. It is suggested that AMPs, which display anticancer activity, should be used in 
combination with conventional chemotherapeutic agents to enhance the effectiveness of these 
treatments, prevent recurrence of cancer following treatment and possibly reduce instances of 
chemotherapy resistance [58, 59]. Other studies have also shown that AMPs have the poten-
tial to enhance the effectiveness of conventional chemotherapeutic agents. The cytotoxicity 
of etoposide and cisplatin could be enhanced through the combination with magainin A and 
magainin G, respectively [60]. More recently, it was shown that the combination of melit-
tin and 5-Fluorouracil enhanced cytotoxic effects against squamous skin cancer cells, while 
simultaneously reducing the toxicity to normal keratinocytes [61]. There are currently no 
AMPs that have entered into clinical trials or that are in preclinical development as cancer 
therapeutics. However, peptide-derived therapies are being recognised for the selectivity and 
anticancer effectiveness and have been investigated in clinical trials [59]. For example, the 
peptide asparagine-glycine arginine tumour homing peptide (NGR-hTNF) has completed 
phase 1 clinical trials and is waiting to enter phase 2 clinical trials to test its effectiveness 
when used in combination with cisplatin for the treatment of several refractory solid tumours 
including melanomas [62].
Based on the findings that nisin Z is more selectively cytotoxic to melanoma cells, the cytotoxic 
effect of the combination of nisin Z with conventional chemotherapeutic agents was investi-
gated in cultured melanoma cells. The effect of combinations of nisin Z with conventional 
chemotherapeutic agents (5-Fluorouracil, etoposide, hydroxyurea) on A375 (melanoma) and 
HaCat (non-malignant keratinocyte) cells was determined by the MTT assay. Cells were 
exposed to different concentrations of the respective chemotherapeutic agents independently 
and in combination with 150 μM of nisin Z for 24 h. Following exposure, the MTT assay was 
performed as described earlier. Blank and background measurements were subtracted and 
cell viability is expressed as a percentage relative to the untreated control, which was set as 
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100% viable. Possible synergistic interactions were evaluated by comparing the cytotoxicity 
of combination treatment with mono-treatment on melanoma cells.
The chemotherapeutic agent 5-Fluorouracil can inhibit RNA and DNA synthesis leading to 
cell death. The combination of nisin Z with 5-Fluorouracil increased the cytotoxicity to mela-
noma cells over the entire concentration range tested compared to the mono-treatment of 
5-Fluorouracil (p < 0.05) (Figure 5A), with no significant increase in toxicity to non-malignant 
keratinocytes (Figure 5B).
The 5-Fluorouracil treatment is initially cytotoxic at 50 μM (p < 0.01 compared to the con-
trol), whereas the combination of 5-Fluorouracil and nisin Z only begins to induce toxicity at 
200 μM (p < 0.001 compared to the control) in the non-malignant keratinocytes. Results indi-
cate that the 5-Fluorouracil-nisin Z combination is more cytotoxic to melanoma cells compared 
to the mono-treatment. The anti-cancer activity of 5-Fluorouracil may, therefore, be enhanced 
by combination treatment with nisin Z. Etoposide is a chemotherapeutic agent that is able to 
induce DNA strand breaks in cancer cells by interfering with type II topoisomerase, ultimately 
inducing apoptosis. When combining etoposide with nisin Z it was found that the activity 
towards melanoma cells was enhanced compared to mono-treatment across the entire concen-
tration range (p < 0.001) (Figure 5C), with no increase in cytotoxicity to non-malignant kerati-
nocytes (Figure 5D). In melanoma cells, the combination of nisin Z with etoposide had a higher 
level of activity at the lowest concentration tested compared to the highest concentration for 
mono-treatment (p < 0.001). The anti-cancer activity of etoposide can, therefore, be significantly 
enhanced through the combination of nisin Z. Hydroxyurea is able to induce DNA damage 
and inhibit DNA synthesis. The combination of nisin Z with hydroxyurea was able to increase 
the cytotoxicity to melanoma cells at concentrations of between 25 and 400 μM compared to 
the mono-treatment of hydroxyurea (p < 0.01) (Figure 5E), with no significant increase in toxic-
ity to non-malignant keratinocytes (Figure 5F).
To evaluate if possible synergistic interactions occurred between the chemotherapeutic agents 
and nisin Z, the cytotoxicity of melanoma cells following the mono-treatment of the respec-
tive chemotherapeutic agents (50 μM) was compared to that of the mono-treatment of nisin Z 
(150 μM), followed by that of the combination (50 μM chemotherapeutic agent +150 μM nisin 
Z). Synergism occurs when the combined effects of the different components are greater than 
their individual effects. The cell viability of melanoma cells was significantly lower for all 
combinations compared to mono-treatment with the chemotherapeutic agent alone (p < 0.05) 
(Figure 6). However, the only combination that displayed synergism was the combination of 
nisin Z with etoposide.
The AMP nisin, which is considered safe for human consumption, not only displays antibacterial 
properties, but also anti-cancer activities. Although the use of nisin as an adjuvant for conven-
tional antibiotics has been investigated extensively, there are few studies investigating nisin as 
an adjuvant for conventional chemotherapeutic agents. Nisin also exhibits immune-modulatory 
properties. We have shown that nisin Z induces selective cytotoxicity towards melanoma cells 
through an apoptotic pathway. These properties make nisin Z an attractive anti-cancer agent to 
be used alone or in combination with current chemotherapeutic agents to enhance anti-cancer 
properties of these agents, while also potentially combatting chemotherapy resistance. Here, 
Cytotoxicity32
it was shown that combinations of nisin Z with 5-Fluorouracil, hydroxyurea and etoposide 
was able to enhance the cytotoxicity to melanoma cells, while no significant increase in toxicity 
toward non-malignant keratinocytes were observed. Especially of interest is the consequence of 
nisin Z on the effectiveness of etoposide, seeing as etoposide resistance is known in melanoma 
[63, 64]. The combination of nisin Z with etoposide was able to significantly and selectively 
Figure 5. Cytotoxicity of chemotherapeutic agents in combination with nisin Z on melanoma (A375) cells and non-
malignant keratinocytes (HaCat) as determined by the MTT assay. (A) Melanoma cells exposed to 5-Fluorouracil (FU) 
combinations. (B) HaCat exposed to 5-FU combinations. (C) Melanoma cells exposed to etoposide combinations. (D) 
HaCat exposed to etoposide combinations. (E) Melanoma cells exposed to hydroxyurea combinations. (F) HaCat 
exposed to hydroxyurea combinations. Vehicle control groups were included and are represented by 0 μM. Results are 
expressed relative to the untreated controls which were set as being 100% viable. Bars represent the standard deviation, 
n = 4. *p < 0.05, **p < 0.01 and *** p < 0.001 for combination compared to chemotherapeutic agent alone.
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enhance the cytotoxic effect etoposide to melanoma cells. Synergism was also observed when 
combining nisin Z and etoposide with regards to the cytotoxic effect in melanoma cells. Based 
on all the properties of nisin Z and its GRAS status it could, therefore, be considered as an adju-
vant for conventional chemotherapeutic agents.
5. Conclusion
The majority of AMPs exhibit direct microbial killing activity and occur in all living species as 
an important part of their innate immune system. Due to the co-evolution of AMPs and bac-
teria, bacterial species are less likely to develop resistance to these peptides compared to con-
ventional antibiotics. The lantibiotic, nisin, has a promising potential for clinical application 
as it exhibits very low cytotoxicity to mammalian cells, while displaying potent antimicrobial 
activity against several common foods borne and clinically important Gram-positive bacteria. 
The use of nisin against Gram-negative bacteria still remains limited. Nisin can be considered 
as a promising adjuvant for antibiotics in the treatment of Gram-positive bacteria. Antibiotic-
nisin combinations can potentially be used to lower the therapeutic dose of antibiotic treat-
ments, while also enhancing the antimicrobial activity by employing multiple modes of action. 
With multiple antimicrobial mechanisms concurrently in play, these combinations can hinder 
the development of antibiotic resistance. We have demonstrated that nisin Z displays syner-
gism when combined with novobiocin against S. aureus. This bacterial species is associated 
with mastitis. Both nisin-based products and novobiocin are used for the treatment of mastitis. 
The synergistic interactions between nisin and novobiocin make this combination, especially 
of interest for developing novel formulations for the treatment of mastitis (Figure 7A).
Apart from the antimicrobial properties of nisin, this AMP also displays promising antican-
cer potential towards several types of malignancies. This chapter discussed the anti-cancer 
potential of nisin Z towards cultured melanoma cells. Results showed that this AMP is more 
Figure 6. Cytotoxicity results for mono-treatment and combinations of chemotherapeutic agents (50 μM) and nisin 
Z (150 μM) as determined by the MTT assay. Nisin Z was combined with (A) etoposide, (B) 5-Fluorouracil and (C) 
hydroxyurea. Bars represent the average and error bars the standard deviation, n = 4. **p < 0.01 and ***p < 0.001 for 
combination compared to chemotherapeutic agent alone. #p < 0.05 and ##p < 0.01 for combination compared to nisin Z 
alone.
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cytotoxic to melanoma cells compared to non-malignant keratinocytes. It was shown that 
nisin Z disrupts the cell membrane integrity of melanoma cells, while also inducing apoptosis 
in the majority of exposed malignant cells (Figure 7B). Taking into account these antican-
cer properties of nisin Z, the cytotoxicity of nisin Z-chemotherapeutic agent combinations 
to melanoma cells was compared to the mono-treatment with selected conventional chemo-
therapeutic agents. This study indicated that when used in combination with the conven-
tional chemotherapeutic agents (5-Fluorouracil, hydroxyurea and etoposide), nisin Z has the 
potential to enhance the cytotoxicity of these conventional chemotherapeutic agents against 
cultured melanoma cells. Synergism was observed between the nisin Z and etoposide com-
bination. However, this study was only limited to the in vitro effect in melanoma cells with 
regards to cytotoxicity as measured by the MTT assay. For future in vitro studies, it is sug-
gested that more cancer cell lines be included. The mechanistic interaction between nisin Z 
and the chemotherapeutic agents should also be investigated. It is also suggested that in vivo 
studies be conducted similarly to that by Preet and co-workers to assess whether the combi-
nation of nisin Z with these conventional chemotherapeutic agents are able to reduce mela-
noma tumorigenesis in vivo [16]. The effective dosages also need to be determined with in vivo 
assays. Nisin Z has great potential for clinical application considering its low cytotoxicity to 
non-malignant cells and the effectiveness of this AMP against Gram-positive bacterial strains 
and certain cancers. However, detailed antimicrobial and anticancer mechanistic interaction 
studies analysis are lacking and many in vitro results must still be confirmed within in vivo 
systems.
Figure 7. Summary of the antimicrobial and anticancer properties of nisin Z alone and in combination with conventional 
therapies. (A) The antimicrobial effects and mechanisms of action of nisin Z and selected antibiotics alone and in 
combination on gram-positive bacteria. (B) The cytotoxic effect of nisin Z on cultured melanoma cells and combinations 
of this AMP with conventional chemotherapeutic agents.
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